Basal insulin for the management of diabetic ketoacidosis

Published: 30 August 2017
Author(s): Leonid Barski, Evgenia Brandstaetter, Iftach Sagy, Alan Jotkowitz
Issue: August 2017
Section: Narrative Review

Due to its pharmacokinetic properties, it has been suggested that long-acting insulin analogues may have a role in facilitating the transition from continuous intravenous insulin infusion to subcutaneous maintenance therapy in patients with DKA for prevention of rebound hyperglycemia, particularly if there are high insulin requirements. Concomitant administration of basal insulin analogues with regular insulin infusion accelerates ketoacidosis resolution and prevents rebound hyperglycemia.Several studies have investigated the use of basal insulin in the management of DKA.